Beta-Lapachone

別名：β-Lapachone, ARQ-501

製品コード：S7261 純度：99.98%

Beta-Lapachone (β-Lapachone, ARQ-501) is a selective DNA topoisomerase I inhibitor, exhibiting no inhibitory activities against DNA topoisomerase II or ligase. Phase 2.

CAS No. 4707-32-8

サイズ	価格(税別)	在庫状況
10mM (1mL in DMSO)	JPY 27600	国内在庫あり
10mg	JPY 17900	国内在庫あり
50mg	JPY 43800	国内在庫あり

代表番号: 045-509-1970\|電子メール：[email protected] よく尋ねられる質問

文献中Selleckの製品使用例（9）

製品安全説明書

現在のバッチを見る：純度： 99.98%

99.98

Beta-Lapachone関連製品

関連ターゲット	Topo I Topo II Topo IV	もっと見る
関連製品	Irinotecan HCl Trihydrate Doxorubicin Idarubicin HCl Mitoxantrone 2HCl Topotecan HCl Irinotecan Epirubicin HCl Topotecan Irinotecan hydrochloride Teniposide Betulinic acid (S)-10-Hydroxycamptothecin Amonafide Levofloxacin Voreloxin (SNS-595) hydrochloride Dexrazoxane HCl Moxifloxacin (BAY12-8039) HCl Ellagic acid Enoxacin Levofloxacin hydrate Gatifloxacin Pixantrone Maleate Ciprofloxacin Ciprofloxacin (CPX) hydrochloride Genz-644282 Ofloxacin Hydroxy Camptothecine Rubitecan	もっと見る
関連化合物ライブラリー	FDA-approved Drug Library Natural Product Library Apoptosis Compound Library DNA Damage/DNA Repair compound Library Cell Cycle compound library	もっと見る

シグナル伝達経路

Topoisomeraseシグナル伝達経路

Topoisomerase阻害剤の選択性比較

生物活性

製品説明

Beta-Lapachone (β-Lapachone, ARQ-501) is a selective DNA topoisomerase I inhibitor, exhibiting no inhibitory activities against DNA topoisomerase II or ligase. Phase 2.

Targets

Topo I ^[1]	IDO1 ^[4]
	0.44 μM

In Vitro
In vitro	Beta-Lapachone inhibits DNA relaxation induced by DNA topoisomerase I in a dose-dependent manner. ^[1] Treatment of beta-lapachone (100 nM or greater) results in >95% inhibition of Topo I DNA unwinding activity compared to the DMSO control. beta-lapachone (1-5 μM) causes a block in G0/G1 of the cell cycle and induces apoptosis by locking Topo I onto DNA and blocking replication fork movement in HL-60 and three human prostate cancer (DU-145, PC-3, and LNCaP) cells. ^[2] Beta-Lapachone facilitates the migration of mouse 3T3 fibroblasts and human endothelial EAhy926 cells through different MAPK signaling pathways, and thus accelerates scrape-wound healing in vitro. ^[3] In addition, beta-Lapachone inhibits purified recombinant IDO1 activity through uncompetitive inhibition with IC50 of 0.44 μM, and beta-lapachone also exhibits superior retention of intracellular IDO1 inhibitory activity with an IC50 of 1.0 μM, partially dependent on biotransformation by NQO1. ^[4] Beta-lapachone induces programmed necrosis of NQO1+ cancer cells by NQO1-dependent reactive oxygen species (ROS) formation and PARP1 hyperactivation. [5]
Kinase Assay	Topoisomerase I Catalytic Actioity Assay ^[1]
Kinase Assay	Topoisomerase I Catalytic Actioity Assay: The enzymatic activity is analyzed by the DNA unwinding assay. DNA topoisomerase I, from TopoGEN (1 unit, which is defined as the amount of enzyme that converts 0.5 μg of superhelical DNA to the relaxed state in 30 minutes at 37 °C), is incubated with 0.5 μg of 6x174 RF DNA, in the presence or absence of Beta-Lapachone, in 20 μL of relaxation buffer (50 mM Tris (pH 7.5). 50 mM KCI, 10 mM MgCl₂, 0.5 mM dithiothreitol, 0.5 mM EDTA, 30 μg/mL bovine serum albumin) for 30 minutes at 37 °C. Reactions are stopped by adding 1% SDS and proteinase K (50 μg/mL). After an additional 1-hour incubation at 37 °C, the products are separated by electrophoresis in 1% agarose gel in TAE buffer (0.04 M tris acetate, 0.001 M EDTA). The gel is stained with ethidium bromide after electrophoresis. The photographic negative is scanned with an NIH image analysis system.
細胞実験	細胞株	HL-60, PC-3, DU145, and LNCaP cells
	濃度	0.005 to 50 μM
	反応時間	12 hours
	実験の流れ	IC50 calculations for each cell line are determined by DNA amount (IS) and anchorage-dependent colony formation (CF) assays. For the CF assay, cells are seeded at 500 viable cells/well in 6-well plates and incubated overnight, then treated with equal volumes of media containing beta-lapachone at final concentrations ranging from 0.005 to 50 μM in half-log increments (controls were treated with 0.25% DMSO, equivalent to the highest dose of beta-lapachonc used) for 4 hour or for continuous 12-hour exposures. Plates (3 wells/condition) are stained with crystal violet, and colonies of >50 normal-appearing cells are enumerated. IC50 values for various cells are calculated using drug doses with numbers of colonies surrounding 50% of control. For DNA assays, plates are harvested for IC50 determinations 8 days after treatment using a CytoFluor 2350 fluorescence measurement system. Six-well samplings are included in the calculation of DNA fluor units for each dose. A graph of beta-lapachone dose versus percentage control DNA in fluor units is used to calculate each IC50. All experiments are repeated at least twice, each in duplicate.

In Vivo
In Vivo	Beta-lapachone treatment (50 mg/kg) leads to potent inhibition of in vivo tumor growth in a xenograft mouse model of human ovarian cancer, and the combination of beta-lapachone and taxol produces a synergistic induction of apoptosis. ^[6] In normal and diabetic (db/db) mice, treatment of beta-lapachone results in a faster healing process than vehicle only. ^[3]
動物実験	動物モデル	Human ovarian cancer cells (36M2) are established in nude mice.
	投与量	25–50 mg/kg
	投与経路	Intraperitoneal administration

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試験 (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT00524524	Completed	Advanced Solid Tumors	ArQule Inc. a subsidiary of Merck Sharp & Dohme LLC a subsidiary of Merck & Co. Inc. (Rahway NJ USA)	August 2007	Phase 1
NCT00622063	Completed	Cancer	ArQule Inc. a subsidiary of Merck Sharp & Dohme LLC a subsidiary of Merck & Co. Inc. (Rahway NJ USA)	December 2006	Phase 1\|Phase 2
NCT00358930	Completed	Head and Neck Neoplasms\|Carcinoma Squamous Cell	ArQule Inc. a subsidiary of Merck Sharp & Dohme LLC a subsidiary of Merck & Co. Inc. (Rahway NJ USA)	July 2006	Phase 2
NCT00102700	Completed	Pancreatic Cancer\|Adenocarcinoma	ArQule Inc. a subsidiary of Merck Sharp & Dohme LLC a subsidiary of Merck & Co. Inc. (Rahway NJ USA)	January 2005	Phase 2
NCT00099190	Completed	Carcinoma	ArQule Inc. a subsidiary of Merck Sharp & Dohme LLC a subsidiary of Merck & Co. Inc. (Rahway NJ USA)	December 2004	Phase 1

参考
[1] Li CJ, et al. J Biol Chem. 1993, 268(30), 22463-22468. [2] Planchon SM, et al. Cancer Res. 1995, 55(17), 3706-3711. [3] Kung HN, et al. Am J Physiol Cell Physiol. 2008, 295(4), C931-943. [4] Flick HE, et al. Int J Tryptophan Res. 2013, 6, 35-45. [5] Huang X, et al. Cancer Res. 2012, 72(12), 3038-3047. [6] Li CJ, et al. Proc Natl Acad Sci U S A. 1999, 96(23), 13369-13374. + 展開

参考

+ 展開

化学情報

分子量	242.27	化学式	C₁₅H₁₄O₃
CAS No.	4707-32-8	SDF	Download Beta-Lapachone SDFをダウンロードする
Smiles	CC1(CCC2=C(O1)C3=CC=CC=C3C(=O)C2=O)C
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1年-80°Cin solvent
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1个月-20°Cin solvent

In vitro
Batch:

DMSO : 33 mg/mL ( (136.21 mM)； Warmed with 50℃ water bath; 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Ethanol : 16 mg/mL

Water : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):